(S (NP (JJ Acute) (NML (NML (NN Kidney)) (NNP Injury) (-LRB- -LRB-) (NNP AKI) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ common) (JJ clinical) (NN syndrome)) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (JJ rapid) (NN loss)) (PP (IN of) (NP (NP (NN kidney) (JJ excretory) (NN function)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ aggravates) (NP (NP (DT the) (JJ clinical) (NN severity)) (PP (IN of) (NP (NP (JJ other) (NNS diseases)) (PP (IN in) (NP (NP (DT a) (JJ large) (NN number)) (PP (IN of) (NP (VBN hospitalized) (NNS patients)))))))))))))))))) (. .))
(S (NP (NP (JJ Accurate) (JJ early) (NN prediction)) (PP (IN of) (NP (NNP AKI)))) (VP (MD can) (VP (VB enable) (PP (IN in) (HYPH -) (NP (NN time) (NNS interventions) (CC and) (NNS treatments))))) (. .))
(S (ADVP (RB However)) (, ,) (S (NP (NNP AKI)) (VP (VBZ is) (ADJP (RB highly) (JJ heterogeneous)))) (, ,) (ADVP (RB thus)) (S (NP (NP (NN identification)) (PP (IN of) (NP (NNP AKI) (NNS sub-phenotypes)))) (VP (MD can) (VP (VB lead) (PP (IN to) (NP (NP (DT an) (JJ improved) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN disease) (NN pathophysiology) (CC and) (NN development)) (PP (IN of) (NP (ADJP (NP (JJR more)) (VBN targeted)) (JJ clinical) (NNS interventions)))))))))) (. .))
(S (NP (DT This) (NN study)) (VP (VBD used) (NP (DT a) (ADJP (NP (NN memory) (NN network)) (HYPH -) (VBN based)) (NML (JJ deep) (NN learning)) (NN approach)) (S (VP (TO to) (VP (VB discover) (NP (NNP AKI) (NNS sub-phenotypes)) (S (VP (VBG using) (NP (NP (ADJP (JJ structured) (CC and) (JJ unstructured)) (NML (NML (JJ electronic) (NN health) (NN record)) (-LRB- -LRB-) (NML (NN EHR)) (-RRB- -RRB-)) (NNS data)) (PP (IN of) (NP (NNS patients)))) (PP (IN before) (NP (NNP AKI) (NN diagnosis))))))))) (. .))
(S (NP (PRP We)) (VP (VBD leveraged) (SBAR (S (NP (NP (DT a) (NML (JJ real) (NN world)) (JJ critical) (NML (NN care) (NN EHR)) (NN corpus)) (PP (VBG including) (NP (CD 37,486) (NN ICU)))) (VP (VBZ stays))))) (. .))
(S (NP (DT These) (NNS patients)) (VP (VBP are) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB develop) (NP (NP (NN stage)) (SBAR (S (NP (PRP I)) (VP (VBP AKI)))))))))) (. .))
(S (NP (DT These) (NNS patients)) (VP (VBP are) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB develop) (NP (NML (NN stage) (CD III)) (NN AKI))))))) (. .))
(S (S (NP (DT Both) (NN SCr) (CC and) (NN eGFR)) (VP (VBP are) (ADJP (RB significantly) (JJ different) (PP (IN across) (NP (NP (DT the) (CD three) (NNS sub-phenotypes)) (PP (IN with) (NP (JJ statistical) (NML (NN testing) (CC plus) (NN postdoc)) (NN analysis)))))))) (, ,) (CC and) (S (NP (DT the) (NN conclusion)) (ADVP (RB still)) (VP (VBZ holds) (PP (IN after) (NP (NN age) (NN adjustment))))) (. .))
